Cannabidiol Suppresses EMT in Pancreatic Cancer via Inhibition of MALAT1 lncRNA and PI3K/Akt/mTOR Signaling Pathway
IUBMB Life · 2025
DOI: 10.1002/iub.70042 ↗Kurz gefasst
Fachartikel in der Zeitschrift IUBMB Life, 2025. Verfasst von Na Young Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Science in Korean Medicine, Kyung Hee University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Epithelial-Mesenchymal Transition, Pancreatic Neoplasms, Cannabidiol. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This research is (partially) funded by the BK21 FOUR program of Graduate School, Kyung Hee University.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is characterized by aggressive metastasis and poor response to chemotherapy, largely driven by epithelial–mesenchymal transition (EMT) and chemokine signaling. Cannabidiol (CBD), a non‐psychoactive phytocannabinoid, has shown anticancer potential, yet its mechanisms in EMT regulation remain underexplored in PDAC. In this study, we demonstrate that CBD significantly suppresses the expression of CXCR4/CXCR7 and matrix metalloproteinases (MMP‐2/9), leading to reduced migration and invasion of MIA PaCa‐2, PANC‐1, and AsPC‐1 cells. Moreover, CBD reversed CXCL12‐induced EMT by downregulating mesenchymal markers and restoring epithelial markers. Mechanistically, CBD inhibited the expression of the long non‐coding RNA MALAT1 , a known EMT regulator, and antagonized its pro‐invasive effects. Overexpression of MALAT1 activated the PI3K/Akt/mTOR pathway and enhanced EMT‐related protein expression, all of which were effectively reversed by CBD. Furthermore, the combination of CBD and gemcitabine exhibited synergistic inhibition of MALAT1 , EMT markers, and PI3K/Akt/mTOR signaling without inducing cytotoxicity, suggesting a therapeutic advantage. Collectively, these findings reveal a novel mechanism through which CBD impedes PDAC metastasis and underscore its promise as a complementary agent in chemotherapy regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Science in Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
- Kyung Hee Institute of Convergence Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
ORCID-Profile: Na Young Kim, Kwang Seok Ahn
Förderung
- This research is (partially) funded by the BK21 FOUR program of Graduate School, Kyung Hee University
Zitieren
APA
Kim, N. Y., Jung, Y. Y., Um, J. Y., & Ahn, K. S. (2025). Cannabidiol Suppresses EMT in Pancreatic Cancer via Inhibition of MALAT1 lncRNA and PI3K/Akt/mTOR Signaling Pathway. IUBMB Life. https://doi.org/10.1002/iub.70042
Vancouver
Kim NY, Jung YY, Um JY, Ahn KS. Cannabidiol Suppresses EMT in Pancreatic Cancer via Inhibition of MALAT1 lncRNA and PI3K/Akt/mTOR Signaling Pathway. IUBMB Life. 2025. doi:10.1002/iub.70042
BibTeX
@article{Kim2025,
author = {Kim, Na Young and Jung, Young Yun and Um, Jae-Young and Ahn, Kwang Seok},
title = {Cannabidiol Suppresses EMT in Pancreatic Cancer via Inhibition of MALAT1 lncRNA and PI3K/Akt/mTOR Signaling Pathway},
journal = {IUBMB Life},
year = {2025},
doi = {10.1002/iub.70042}
}
EUVIMED